---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019016"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:30:02.194311+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Armata Q3 loss from ops $(10.3)M; cash $24M; AP-SA02 and AP-PA02 enrollment accelerating

## Summary
- Grant revenue $1.2M (vs $1.3M); R&D $8.0M (vs $8.4M); G&A $3.6M (vs $1.6M) due to one-time financing costs.
- Loss from operations widened to $(10.3)M from $(8.6)M YoY.
- Cash $24.0M as of Sept 30 vs $14.9M Dec 31, 2022; $25M credit agreement with Innoviva signed July 2023.
- Phase 2a diSArm (AP-SA02) and Phase 2 Tailwind (AP-PA02) enrollment accelerating; expects Phase 2 diSArm completion in 2024.
- Shares outstanding ~36.1M as of Nov 14, 2023.

## SEC filing metadata
- accession: 0001558370-23-019016
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/0001558370-23-019016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/armp-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019016
- JSON: https://secwatch.observer/filing/0001558370-23-019016.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019016.txt

## Key facts
- Earnings Releases
  Armata Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue grant revenue of approximately $1.2 million.
  - Period: three months ended September 30, 2023
  - Revenue: grant revenue of approximately $1.2 million
  - Result: reported results
  source text: through the remainder of the year and into 2024,” Dr. Birx concluded. Third Quarter 2023 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.2 million for the three months ended September 30, 2023, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000155837023019016/0001558370-23-019016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.